CNInvesting wrote: 1. I know, it's not a cash-generating business for CXR. That is as of yet. Recent criticism of the pharma industry included the fact that no capital goes to R&D. While it's true for most companies, shorts are happy to neglect saying that CXR is in no such position. There are no huge amounts spent on R&D, it's true, but R&D for it's own sake is pointless. It needs to make a difference in the end.
2. Pinnacle Biologics actually set CXR appart from other pharma companies because ,as small as it is now, it could actually help cure with Photofrin and PDT a rare form of cancer with no current cure.
3. The market is small true, but CXR always maintained that it focused on niche markets. This is one of them. Investors, public and private, will love the fact that it could give CXR exposure to Asia through its agreement with UnionMed. Bile duct cancer is more prevalent in South-East Asia.
4. In the US, it's estimated that there will be 39,230 new cases of such form of cancers in 2016. It's been rising at a rate of about 3% over the last 10 years. The mortality rate is high with only 17.5% surviving after 5 years.
5. The news we've got about the progress on the Photofrin trial is very good. It's been in the works for a long time and the fact that everything is going in a positive direction so far is a much needed positive amidst all the bad ( unwarrented ) press of late.
6. If it continues on a positive note, this type of progress could help CXR to position itself as a specialty pharma leader for this form of cancer and help the company get a ''moat'' over competitors for this rare disease.
Links for anyone interested in learning on the matte. I took the numbers from the National Cancer Institute:
https://www.cancer.org/acs/groups/cid/documents/webcontent/003084-pdf.pdf https://seer.cancer.gov/statfacts/html/livibd.html https://www.cancerresearchuk.org/about-cancer/type/bile-duct-cancer/bile-duct-cancer-treatment/statistics-outlook-bile-duct-cancer https://concordiarx.com/concordia-healthcare-announces-pdt-with-photofrin-data-and-provides-corporate-update/